Skip to content
Brukinsa(zanubrutinib)
Brukinsa (zanubrutinib) is a small molecule pharmaceutical. Zanubrutinib was first approved as Brukinsa on 2019-11-14. It is used to treat mantle-cell lymphoma in the USA. It has been approved in Europe to treat waldenstrom macroglobulinemia. It is known to target tyrosine-protein kinase BTK.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Brukinsa
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zanubrutinib
Tradename
Company
Number
Date
Products
BRUKINSABeigeneN-213217 RX2019-11-14
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
brukinsaNew Drug Application2020-08-06
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
mantle-cell lymphoma—D020522C83.1
Agency Specific
FDA
EMA
Expiration
Code
ZANUBRUTINIB, BRUKINSA, BEIGENE
2030-01-19ODE-274
2028-09-14ODE-370
2028-08-31ODE-371
2026-11-14ODE-276
2026-01-19I-817
2024-11-14NCE
2024-09-14I-874
2024-08-31I-871
Patent Expiration
Patent
Expires
Flag
FDA Information
Zanubrutinib, Brukinsa, Beigene
109271172037-08-15DS, DP
115913402037-08-15U-1745, U-2145, U-2537, U-2666, U-3063, U-3486
94471062034-04-22DS, DPU-1745, U-2145, U-2537, U-2666, U-3063, U-3486
105701392034-04-22U-1745, U-2145, U-2537, U-2666, U-3063, U-3486
111425282034-04-22DPU-1745, U-2145, U-2537, U-2666, U-3063, U-3486
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EL: Bruton's tyrosine kinase (btk) inhibitors
— L01EL03: Zanubrutinib
HCPCS
No data
Clinical
Clinical Trials
93 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Large b-cell lymphoma diffuseD016403C83.33142——18
B-cell chronic lymphocytic leukemiaD015451C91.12102——13
Mantle-cell lymphomaD020522C83.1262——9
Waldenstrom macroglobulinemiaD008258C88.0—31—37
Non-hodgkin lymphomaD008228C85.9111——3
Hodgkin diseaseD006689C81——1——1
Membranous glomerulonephritisD015433EFO_0004254N03.2—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Thrombocytopenic purpura idiopathicD016553EFO_0007160D69.314———4
Follicular lymphomaD008224C8222———3
NeoplasmsD009369C8012———2
B-cell lymphomaD01639311———2
TherapeuticsD013812—2———2
Lymphoid leukemiaD007945C91—1———1
Lupus nephritisD008181EFO_0005761—1———1
Immunoglobulin g4-related diseaseD000077733—1———1
Covid-19D000086382U07.1—1———1
Non-small-cell lung carcinomaD00228911———1
Show 6 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—7————7
B-cell lymphoma marginal zoneD018442C88.41————1
Hepatic insufficiencyD0485501————1
LeukemiaD007938C951————1
LymphomaD008223C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameZANUBRUTINIB
INNzanubrutinib
Description
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
Classification
Small molecule
Drug classtyrosine kinase inhibitors: tyrosine kinase inhibitors Bruton's (Btk) inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
Identifiers
PDB—
CAS-ID1691249-45-2
RxCUI—
ChEMBL IDCHEMBL3936761
ChEBI ID—
PubChem CID135565884
DrugBankDB15035
UNII IDAG9MHG098Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BTK
BTK
Organism
Homo sapiens
Gene name
BTK
Gene synonyms
AGMX1, ATK, BPK
NCBI Gene ID
695
Protein name
tyrosine-protein kinase BTK
Protein synonyms
agammaglobulinaemia tyrosine kinase, Agammaglobulinemia tyrosine kinase, ATK, B-cell progenitor kinase, BPK, Bruton agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, Bruton's tyrosine kinase, dominant-negative kinase-deficient Brutons tyrosine kinase
Uniprot ID
Q32ML5
Mouse ortholog
Btk (12229)
tyrosine-protein kinase BTK (Q61365)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 859 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,869 adverse events reported
View more details